A Milestone-based approach to monitoring disease progression in Parkinson’s disease
Objective: We used Parkinson Progression Marker Initiative (PPMI) data to assess the frequency of clinically meaningful disease milestones and examine baseline predictors of reaching these…The ADOPTION (eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs) study in Parkinson’s disease: design and rationale of a randomized prospective, open-label exploratory trial
Objective: This study aims to explore the potential of opicapone (OPC) to optimize levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) as first-line approach to treat wearing-off in…Re-thinking enrollment of Deep Brain Stimulation patients in Parkinson’s Disease Clinical Trials
Objective: To report on a survey of Parkinson’s disease (PD) experts on the inclusion of PD patients with deep brain stimulation (DBS) in clinical trials.…The Role of the PD Diary Trainer/Reviewer in Parkinson’s Disease Clinical Trials
Objective: To examine the experience profile of PD Diary raters in clinical trials Background: The Parkinson’s Disease (PD) Home Diary (Hauser, 2000)1 is a widely…Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial
Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…Impact of specialized light therapy in Parkinson’s disease on MDS-UPDRS parts 1-3 subscales
Objective: An exploratory analysis to examine the MDS-UPDRS 1-3 subitems of PD patients who underwent specialized light therapy (SLT) to assess the breadth of impact…Effect of oxytocin on response inhibition in Parkinson´s disease: a pilot study
Objective: To observe the effect of oxytocin (OXT) on response inhibition in Parkinson´s disease (PD) patients using dedicated saccadic tasks. Background: Cumulating evidence has shown…Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…Neuroprotective Epigenetic and DNA-Repair Molecular Mechanisms of Acetyl-L-Carnitine and Astaxanthin Against 6-OHDA Induced Parkinsonism in Aged Rats
Objective: Present study was designed to delineate the neuroprotective epigenetic and DNA-damage-repair molecular mechanisms of acetyl-L-carnitine (ALC) and astaxanthin (ASX) against 6-OHDA-induced neurotoxicity in aged…Associations between Exercise Classes and Self-Reported Exercise by People with Parkinson’s Disease at Parkinson’s Foundation Centers of Excellence
Objective: We sought to examine the relationship between the characteristics of Parkinson’s Foundation Center of Excellence (COE)-based and community-based exercise classes and the self-reported hours…
- « Previous Page
- 1
- …
- 74
- 75
- 76
- 77
- 78
- …
- 132
- Next Page »